Sanofi Pasteur Sa

Sanofi Pasteur Inc.

Aventis Pasteur S.a.

Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Catherine Moste

Isabelle Legastelois

Michel Chevalier

Michel Joseph Bublot

Suryaprakash Sambhara

François-Xavier Le Gros

Julie Medina

Bernard Meignier

Laurent Thion

Catherine Gerdil

Michel Joseph Marie Bublot

The invention relates to a method for producing influenza infectious viruses wherein CHO cells are infected with a seed of infectious influenza virus which has been generated by transfecting cells with an appropriate set of expression vectors. The invention also relates to a recombination cassette, and to a vector comprising said recombination cassette, that may be used in methods for producing infectious viruses, and particularly in the method according to the invention.

Production of infectious influenza viruses

The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.

Flu virus hemagglutinin specific monoclonal antibodies

The invention relates to a method for producing flu virus according to which:

Method for producing the flu virus

The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.

Use of poxviruses as enhancer of specific immunity

Growing community of inventors

Charbonnieres les bains, France

Catherine Moste